#### SYSTEM LOCATION:

Federal Housing Finance Agency, 400 Seventh Street SW, Washington, DC 20219, and any alternate work site utilized by employees of the Federal Housing Finance Agency (FHFA) or by individuals assisting such employees.

## SYSTEM MANAGER(S):

Office of General Counsel, Federal Housing Finance Agency, 400 Seventh Street SW, Washington, DC 20219.

#### PURPOSE(S) OF THE SYSTEM:

The purpose of the System is expanded to include collecting information from other organizations and entities that voluntarily submit reports to FHFA about counterparties that have engaged in covered misconduct as defined in the Suspended Counterparty Regulation at 12 CFR 1227.2.

#### ROUTINE USES OF RECORDS MAINTAINED IN THE SYSTEM, INCLUDING CATEGORIES OF USERS AND THE PURPOSE OF SUCH USES:

(13) To an FHFA regulated entity.

(14) To state and federal housing or financial regulators.

(15) To state or federal professional licensing agencies.

#### HISTORY:

The FHFA Suspended Counterparty System (FHFA–23) system of records was last published in the **Federal Register** on November 25, 2014 (79 FR 70181).

Dated: February 28, 2018.

### Melvin L. Watt,

Director, Federal Housing Finance Agency. [FR Doc. 2018–04527 Filed 3–5–18; 8:45 am] BILLING CODE 8070–01–P

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)— SIP18–001, Targeting Treatment Gaps: Describing When, How Quickly, And Why Persons with Epilepsy Are Referred For Specialty Care.

*Date:* April 25, 2018.

*Time:* 11:00 a.m.–4:00 p.m., EDT. *Place:* Teleconference.

*Agenda:* To review and evaluate grant applications.

*For Further Information Contact:* Jaya Raman, Ph.D., Scientific Review Officer, CDC, 4770 Buford Highway, Mailstop F80, Atlanta, Georgia 30341, Telephone: (770) 488–6511, *kva5@cdc.gov*.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

### Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2018–04479 Filed 3–5–18; 8:45 am] BILLING CODE 4163–18–P

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Centers for Disease Control and Prevention

## Advisory Council for the Elimination of Tuberculosis Meeting (ACET)

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). **ACTION:** Notice of meeting.

SUMMARY: In accordance with the Federal Advisory Committee Act, the CDC announces the following meeting of the Advisory Council for the Elimination of Tuberculosis Meeting (ACET). This meeting is open to the public, limited only by 100 room seating and 100 ports for audio phone lines. Time will be available for public comment. The public is welcome to submit written comments in advance of the meeting. Comments should be submitted in writing by email to the contact person listed below. The deadline for receipt is Monday, April 9, 2018. Persons who desire to make an oral statement, may request it at the

time of the public comment period on April 17, 2018 at 3:20 p.m. EDT. This meeting is accessible by web conference: 1–877–927–1433 and participant passcode: 12016435 and https://adobeconnect.cdc.gov/ r5p8l2tytpq/.

**DATES:** The meeting will be held on April 17, 2018, 8:30 a.m. to 3:30 p.m., EDT.

**ADDRESSES:** 8 Corporate Blvd., Building 8, Conference Rooms 1A and 1B, Atlanta, Georgia, 30329 and web conference.

# FOR FURTHER INFORMATION CONTACT:

Margie Scott-Cseh, Committee Management Specialist, CDC, 1600 Clifton Road NE, Mailstop: E–07, Atlanta, Georgia, 30329, telephone (404) 639–8317; zkr7@cdc.gov.

## SUPPLEMENTARY INFORMATION:

*Purpose:* This Council advises and makes recommendations to the Secretary of Health and Human Services, the Assistant Secretary for Health, and the Director, CDC, regarding the elimination of tuberculosis. Specifically, the Council makes recommendations regarding policies, strategies, objectives, and priorities; addresses the development and application of new technologies; and reviews the extent to which progress has been made toward eliminating tuberculosis.

Matters to be Considered: The agenda will include: (1) Update on Report of Verified Case of Tuberculosis (RVCT) revision; (2) Overview of Division of Global Migration and Quarantine (DGMQ) TB Technical Instructions; (3) Update on healthcare workers screening guidelines; and (4) Updates from ACET workgroups. Agenda items are subject to change as priorities dictate.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

#### Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2018–04477 Filed 3–5–18; 8:45 am]

BILLING CODE 4163-18-P